Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2975-2983

  Lee, Changkyu ^a   Choi, Ji Su ^a   Kim, Insoo ^a   Oh, Kyung Taek ^b   Lee, Eun Seong ^c   Park, Eun Seok ^a   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Chung Ang University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Chitosan coating; Exendin 4; Inhalation; PLGA nanoparticles; Type 2 diabetes

Indexed keywords

CHITOSAN; EXENDIN 4; PALMITIC ACID; POLYGLACTIN;

ACUTE TOXICITY; ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL ADHESION; COATED PARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HYDROPHOBICITY; HYPOGLYCEMIA; LUNG ALVEOLUS EPITHELIUM; MALE; MORPHOLOGY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL;

CHITOSAN-COATING; EXENDIN-4; INHALATION; PLGA NANOPARTICLES; TYPE 2 DIABETES;

ADMINISTRATION, INHALATION; ADSORPTION; ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; CELL LINE; CELL SURVIVAL; CHITOSAN; DIABETES MELLITUS, TYPE 2; DRUG CARRIERS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PEPTIDES; POLYGLYCOLIC ACID; SURFACE PROPERTIES; VENOMS;

EID: 84881503529     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S48197     Document Type: Article

References (33)

1. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
2. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338-344.
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19(1):3-36.
4. Lee J, Lee C, Kim I, etal. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int J Pharm. 2012;424(1-2):50-57.
5. Lee J, Lee C, Kim TH, etal. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice. Regul Pept. 2012;177(1-3):68-72.
6. Kim H, Lee J, Kim TH, etal. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res. 2011;28(8):2008-2019.
7. Kim H, Park H, Lee J, etal. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials. 2011;32(6):1685-1693.
8. Youn YS, Lee KC, Bae YH, Na K, Lee ES. Advanced pulmonary delivery of peptides or proteins using polymeric particles. In: Jorgensen L, Nielsen HM, editors. Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids, and Vaccines. Hoboken: Wiley; 2009:228-244.
9. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563-570.
10. Yang R, Shim WS, Cui FD, etal. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm. 2009;371(1-2):142-147.
11. Lauweryns JM, Baert JH. Alveolar clearance and the role of the pulmonary lymphatics. Am Rev Respir Dis. 1977;115(4):625-683.
12. Makhlof A, Werle M, Tozuka Y, Takeuchi H. Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. Int J Pharm. 2010;397(1-2):92-95.
13. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release. 2005;102(2):373-381.
14. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm. 2001;218(1-2):75-80.
15. Censi R, Di Martino P, Vermonden T, Hennink WE. Hydrogels for protein delivery in tissue engineering. J Control Release. 2012;161(2): 680-692.
16. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010;62(1):83-99.
17. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2010;62(1):28-41.
18. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee DS. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release. 2010;144(1):10-16.
19. Chae SY, Jin CH, Shin JH, etal. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010;142(2):206-213.
20. Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci. 2012:45(5):632-638.
21. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev. 2001;47(1): 39-54.
22. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009;382(1-2):198-204.
23. Tahara K, Yamamoto H, Kawashima Y. Cellular uptake mechanisms and intracellular distributions of polysorbate 80-modified poly (D, L-lactide-co-glycolide) nanospheres for gene delivery. Eur J Pharm Biopharm. 2010;75(2):218-224.
24. Lee J, Lee C, Kim TH, etal. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system. J Control Release. 2012;161(3): 728-734.
25. Choi M, Cho M, Han BS, etal. Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol Lett. 2010;199(2):144-152.
26. Nafee N, Schneider M, Schaefer UF, Lehr CM. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm. 2009;381(2):130-139.
27. Grenha A, Grainger CI, Dailey LA, etal. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci. 2007;31(2):73-84.
28. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62(1-2):279-287.
29. Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm. 2011;409(1-2): 111-120.
30. Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive. Biomacromolecules. 2008;9(7):1837-1842.
31. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183.
32. Chuang VT, Kragh-Hansen U, Otagiri M, Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19(5): 569-577.
33. Huang YC, Vieira A, Huang KL, Yeh MK, Chiang CH. Pulmonary inflammation caused by chitosan microparticles. J Biomed Mater Res A. 2005;75(2):283-287.